RxDoctor Payments Data

Russell Ross, APRN

Family · San Antonio, TXNPI 1619526761

Payments from drug & device makers

$5,693in general payments, 2019–2025

Across 342 payments — averaging $16.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Pfizer$532
  • Novo Nordisk$458
  • Bayer$450
  • Lilly USA, LLC$287
  • AstraZeneca$214
  • plus $2K from 43 others

What the payments were for

  • Food & beverage$5,674100%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,693 in reported general payments places this provider in the 90th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$48,931
Medicare patients
265
Services billed
876

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol121$115,026
OzempicSemaglutide63$70,488
JardianceEmpagliflozin39$55,661
EliquisApixaban22$27,579
Breztri AerosphereBudesonide/Glycopyr/Formoterol41$26,193
MyrbetriqMirabegron20$24,815
Spiriva RespimatTiotropium Bromide29$15,748
MounjaroTirzepatide15$15,659
VascepaIcosapent Ethyl15$12,454
Varenicline Tartrate11$3,730
Fluticasone Propionate240$2,935
Levothyroxine Sodium129$2,583
Fluticasone-SalmeterolFluticasone Propion/Salmeterol28$2,507
Albuterol Sulfate HfaAlbuterol Sulfate122$2,405
Azelastine Hcl83$2,331

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$214$141,220162 claims
Boehringer IngelheimJardiance, Spiriva Respimat$114$71,41068 claims
Novo NordiskOzempic$458$70,48863 claims
PfizerEliquis$532$27,57922 claims
Astellas Pharma US IncMyrbetriq$41$24,81520 claims
Lilly USA, LLCMounjaro$287$15,65915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 15,456 family providers in Texas.

Other family in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →